Tango Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

Tango Therapeutics' latest filing reveals a significant shake-up in its board composition coinciding with the release of its quarterly financial results. While the company frames the transition as a routine leadership change, the loss of its Lead Independent Director and a key committee chair creates a vacuum of experienced oversight. Investors must now weigh whether this is a calculated move to streamline governance for a future exit or a symptom of deeper institutional instability that could jeopardize the company's clinical execution.